Skip to content
Cabergoline
Dostinex (cabergoline) is a small molecule pharmaceutical. Cabergoline was first approved as Dostinex on 1996-12-23. It is used to treat adenoma, hyperprolactinemia, and parkinson disease in the USA. It is known to target 5-hydroxytryptamine receptor 2A, D(1A) dopamine receptor, 5-hydroxytryptamine receptor 1A, alpha-1A adrenergic receptor, alpha-2A adrenergic receptor, D(1B) dopamine receptor, D(3) dopamine receptor, 5-hydroxytryptamine receptor 2C, alpha-2B adrenergic receptor, 5-hydroxytryptamine receptor 2B, D(2) dopamine receptor, alpha-2C adrenergic receptor, D(4) dopamine receptor, 5-hydroxytryptamine receptor 1B, and 5-hydroxytryptamine receptor 1D.
Download report
Favorite
Commercial
Therapeutic Areas
Therapeutic Area
MeSH
neoplasmsD009369
nervous system diseasesD009422
endocrine system diseasesD004700
Trade Name
FDA
EMA
No data
Drug Products
FDA
EMA
New Drug Application (NDA)
New Drug Application (NDA)
Abbreviated New Drug Application (ANDA)
Abbreviated New Drug Application (ANDA)
Cabergoline
Tradename
Company
Number
Date
Products
DOSTINEXMylanN-020664 DISCN1996-12-23
1 products, RLD
Hide discontinued
Labels
FDA
EMA
Brand Name
Status
Last Update
cabergolineANDA2023-05-15
Indications
FDA
EMA
Indication
Ontology
MeSH
ICD-10
adenomaD000236
hyperprolactinemiaD006966E22.1
parkinson diseaseEFO_0002508D010300G20
Agency Specific
FDA
EMA
No data
Patent Expiration
No data
ATC Codes
G: Genito urinary system and sex hormones
G02: Other gynecologicals in atc
G02C: Other gynecologicals in atc
G02CB: Prolactine inhibitors
G02CB03: Cabergoline
N: Nervous system drugs
N04: Anti-parkinson drugs
N04B: Dopaminergic agents
N04BC: Dopamine agonists
N04BC06: Cabergoline
HCPCS
Code
Description
J8515
Cabergoline, oral, 0.25 mg
Clinical
Clinical Trials
57 clinical trials
View more details
Mock data
Subscribe for the real data
Indications Phases 4
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Chronic hepatitis cD019698EFO_0004220B18.216143528
Hepatitis cD006526B19.23352114
HivD006678O98.71113
Chronic kidney failureD007676EFO_0003884N18.6112
HepatitisD006505HP_0012115K75.911
Indications Phases 3
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Hiv infectionsD015658EFO_0000764B201225
HepacivirusD0161741112
Chronic hepatitis bD019694EFO_0004197B18.1112
MenopauseD008593EFO_0003922N9511
CoinfectionD06008511
Indications Phases 2
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Healthy volunteers/patients313
Experimental liver cirrhosisD00810611
Indications Phases 1
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Papillomavirus infectionsD03036122
ThrombocytopeniaD013921HP_0001873D69.611
Liver transplantationD016031EFO_001068211
Indications Without Phase
Indication
MeSH
Ontology
ICD-10
Ph 1
Ph 2
Ph 3
Ph 4
Other
Total
Liver cirrhosisD008103EFO_0001422K74.022
Epidemiology
Epidemiological information for investigational and approved indications
View more details
Drug
General
Drug common nameCABERGOLINE
INNcabergoline
Description
Cabergoline is an N-acylurea that is (8R)-ergoline-8-carboxamide in which the hydrogen attached to the piperidine nitrogen (position 6) is substituted by an allyl group and the hydrogens attached to the carboxamide nitrogen are substituted by a 3-(dimethylamino)propyl group and an N-ethylcarbamoyl group. A dopamine D2 receptor agonist, cabergoline is used in the management of Parkinson's disease and of disorders associated with hyperprolactinaemia. It has a role as a dopamine agonist, an antiparkinson drug and an antineoplastic agent.
Classification
Small molecule
Drug classergot alkaloid deriviatives
Image (chem structure or protein)
Structure (InChI/SMILES or Protein Sequence)
C=CCN1C[C@H](C(=O)N(CCCN(C)C)C(=O)NCC)C[C@@H]2c3cccc4[nH]cc(c34)C[C@H]21
Identifiers
PDB
CAS-ID81409-90-7
RxCUI47579
ChEMBL IDCHEMBL1201087
ChEBI ID3286
PubChem CID54746
DrugBankDB00248
UNII IDLL60K9J05T (ChemIDplus, GSRS)
Target
Agency Approved
No data
Alternate
HTR2A
HTR2A
DRD1
DRD1
HTR1A
HTR1A
ADRA1A
ADRA1A
ADRA2A
ADRA2A
DRD5
DRD5
DRD3
DRD3
HTR2C
HTR2C
ADRA2B
ADRA2B
HTR2B
HTR2B
DRD2
DRD2
ADRA2C
ADRA2C
DRD4
DRD4
HTR1B
HTR1B
HTR1D
HTR1D
Organism
Homo sapiens
Gene name
HTR2A
Gene synonyms
HTR2
NCBI Gene ID
Protein name
5-hydroxytryptamine receptor 2A
Protein synonyms
5-HT2 receptor, 5-hydroxytryptamine (serotonin) receptor 2A, G protein-coupled, serotonin 5-HT-2A receptor, Serotonin receptor 2A
Uniprot ID
Mouse ortholog
Htr2a (15558)
5-hydroxytryptamine receptor 2A (P35363)
Variants
Clinical Variant
No data
Financial
No data
Trends
PubMed Central
Top Terms for Disease or Syndrome:
Mock data
Subscribe for the real data
Additional graphs summarizing 3,439 documents
View more details
Safety
Black-box Warning
No Black-box warning
Adverse Events
Top Adverse Reactions
Mock data
Subscribe for the real data
10,101 adverse events reported
View more details